[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611424":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":30,"centralContacts":31,"locations":30,"responsibleParty":37,"collaborators":30,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":30,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":30,"maxAge":30,"enrollmentInfo":49,"targetDuration":30,"studyType":52,"phases":53,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":62,"whyStopped":30,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":30},{"fullName":5,"class":6},"Kafrelsheikh University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Group D","EXPERIMENTAL","Patients will receive ACB using 20 ml of bupivacaine 0.25%+ 0.5 µg\u002Fkg dexmedetomidine.",[13],"Drug: Adductor Canal Block (ACB) Only",{"label":15,"type":10,"description":16,"interventionNames":17},"Group M","Patients will receive ACB using 20 ml of bupivacaine 0.25%\n\n+0.1 mg\u002Fkg morphine.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Group C","Patients will receive ACB using 20 ml of bupivacaine 0.25% alone as a control group.",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Adductor Canal Block (ACB) Only","This study aims to compare morphine and dexmedetomidine as adjuvants to bupivacaine in ultrasound-guided ACB for postoperative analgesia after knee surgeries. Primary outcome:\n\n• Time to first rescue analgesia .\n\nSecondary outcomes:\n\n* Total opioid consumption in 24 hours postoperatively.\n* Degree of pain using visual analogue scale (VAS).\n* Degree of patient satisfaction.\n* Incidence of complication A) Related to block Nerve Injury Vascular Puncture Hematoma B) Related to drug Local Anesthetic Systemic Toxicity (LAST)",[19,9,15],[29],"adductor canal block",null,[32],{"name":33,"role":34,"phone":35,"phoneExt":30,"email":36},"Ashraf Abd El-Nasser Abd El-Hamid kamel El Rewany Anesthesia KafrElsheikh University Faculty of Medicine Anesthesia, Surg, MBBCH","CONTACT","+201061195395","ashraf.elrewany2@gmail.com",{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"PRINCIPAL_INVESTIGATOR","Ashraf Abd El-Nasser Abd El-Hamid","Ashraf Elrewany","100611424","phase-1-compare-morphine-and-dexmedetomidine-as-adjuvants-to-bupivacaine-in-ultrasound-guided-acb-for-postoperative-analgesia-after-knee-surgeries-100611424",false,"NCT07240402","Compare Morphine and Dexmedetomidine as Adjuvants to Bupivacaine in Ultrasound-guided ACB for Postoperative Analgesia After Knee Surgeries","Comparative Study of Morphine and Dexmedetomidine as Adjuvants to Bupivacaine in Ultrasound-Guided Adductor Canal Block for Postoperative Analgesia After Knee Surgeries","Inclusion criteria:\n\n* Both sexes.\n* American Society of Anesthesiologists (ASA) physical status I-II.\n* Body mass index (BMI) of 20-35 kg\u002Fm2.\n* Undergoing knee surgeries under spinal anesthesia.\n\nExclusion criteria:\n\n* Any known allergy or contraindication to local anesthetic.\n* History of substance abuse.\n* Decompansated cardiac, pulmonary, hepatic, renal disease.\n* Obese patients with BMI\\>35kg\u002Fm2.\n* Pregnant and lactating mothers.\n* Coagulopathies.\n* Local skin infections at the site of injection.","ALL",{"count":50,"type":51},15,"ESTIMATED","INTERVENTIONAL",[54,55],"PHASE1","PHASE2","This study aims to compare morphine and dexmedetomidine as adjuvants to bupivacaine in ultrasound-guided ACB for postoperative analgesia after knee surgeries",[58,59],"Postoperative Analgesia","Morphine and Dexmedetomidine",[61],"Adductor Canal Block","NOT_YET_RECRUITING","2025-11-16",{"date":65,"type":66},"2025-11-20","ACTUAL",{"date":68,"type":51},"2025-11-17",{"date":70,"type":51},"2026-02-01",{"name":5,"class":6}]